Patents by Inventor Masanao Matsuo
Masanao Matsuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9261443Abstract: Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.Type: GrantFiled: May 8, 2013Date of Patent: February 16, 2016Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
-
Patent number: 9097714Abstract: To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence. The method for determining the presence of a malignant tumor or the severity thereof, method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or method for estimating the risk of recurrence of the malignant tumor or the presence or absence of the recurrence is characterized by including 1) a step of measuring the concentration and/or quantity of soluble LR11 in a sample originating from a subject and 2) a step of comparing the value measured above with a measurement value of soluble LR11 obtained from a healthy subject group.Type: GrantFiled: December 15, 2010Date of Patent: August 4, 2015Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Hiroyuki Ebinuma, Kohei Takubo, Masanao Matsuo, Isamu Fukamachi, Hideaki Bujo, Chiaki Nakaseko, Yasushi Saito
-
Publication number: 20130029363Abstract: To provide a method and a diagnostic kit for determining the presence of a malignant tumor or the severity thereof, a method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or a method for estimating the risk of recurrence of the malignant tumor or determining the presence or absence of the recurrence. The method for determining the presence of a malignant tumor or the severity thereof, method for selecting a therapeutic method therefor or evaluating the effect of the therapeutic method, or method for estimating the risk of recurrence of the malignant tumor or the presence or absence of the recurrence is characterized by including 1) a step of measuring the concentration and/or quantity of soluble LR11 in a sample originating from a subject and 2) a step of comparing the value measured above with a measurement value of soluble LR11 obtained from a healthy subject group.Type: ApplicationFiled: December 15, 2010Publication date: January 31, 2013Applicant: Sekisui Medical Co., Ltd.Inventors: Hiroyuki Ebinuma, Kohei Takubo, Masanao Matsuo, Isamu Fukamachi, Hideaki Bujo, Chiaki Nakaseko, Yasushi Saito
-
Publication number: 20110177610Abstract: Disclosed is a novel marker for an arteriosclerotic disease. Also disclosed is a method for evaluating the presence or level of an arteriosclerotic disease in a mammal, or a method for evaluating the prophylactic or therapeutic effect on an arteriosclerotic disease in a mammal, which is characterized by detecting a soluble LR11 in a sample collected from the mammal.Type: ApplicationFiled: June 13, 2008Publication date: July 21, 2011Applicant: SEKISUI MEDICAL CO., LTD.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
-
Publication number: 20110091993Abstract: Provided is a method for quantifying soluble LR11 in a biological sample such as serum by an immunological means conveniently and accurately without the need of carrying out any complicated separation manipulation. An immunological quantification method for soluble LR11 in a sample derived from a mammal, including a step of treating the sample with at least one surfactant selected from a group consisting of a polyoxyalkylene alkyl ether, a polyoxyalkylene alkyl phenyl ether, an alkyl glycoside, an alkylthio glycoside, an acyl-N-methylglucamide and a salt of cholic acid.Type: ApplicationFiled: March 17, 2009Publication date: April 21, 2011Applicant: Sekisui Medical Co., Ltd.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Isamu Fukamachi, Hideaki Bujo, Yasushi Saito
-
Patent number: 7829294Abstract: The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an A?-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.Type: GrantFiled: December 27, 2005Date of Patent: November 9, 2010Assignee: Daiichi Pure Chemicals Co., Ltd.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Osamu Miyazaki, Kyoko Tanaka, Akiko Suzuki
-
Publication number: 20080044926Abstract: It is intended to provide a reagent and an assay method whereby an antigen can be conveniently and accurately assayed without resorting to any special antibody. Using two or more carriers having different particle sizes, a carrier having a smaller particle size is sensitized with at least one monoclonal antibody, which is selected from among three monoclonal antibodies being reactive with both of a free antigen and a complex antigen and having different recognition sites from each other, while a carrier having a larger particle size is sensitized with the remainder monoclonal antibodies, thereby providing an assay reagent and an assay method whereby the reactivities of a free antigen and a complex antigen can be controlled.Type: ApplicationFiled: December 22, 2005Publication date: February 21, 2008Applicant: DAIICHI PURE CHEMICALS CO.,Inventors: Yuki Honjo, Yuka Akimoto, Kazuo Kotani, Hirokazu Yago, Masanao Matsuo, Osamu Miyazaki, Kazunori Saito
-
Publication number: 20080009077Abstract: The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an A?-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.Type: ApplicationFiled: December 27, 2005Publication date: January 10, 2008Applicant: Daiichi Pure Chemicals Co., Ltd.Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Osamu Miyazaki, Kyoko Tanaka, Akiko Suzuki